Clinical Trials
358
Active:294
Completed:26
Trial Phases
5 Phases
Phase 1:207
Phase 2:13
Phase 3:41
+2 more phases
Drug Approvals
7
FDA:6
NMPA:1
Drug Approvals
Emtricitabine and tenofovir disoproxil fumarate tablets
- Product Name
- 舒发泰
- Approval Number
- 国药准字HJ20200025
- Approval Date
- Apr 25, 2022
NMPA
Clinical Trials
Distribution across different clinical trial phases (274 trials with phase data)• Click on a phase to view related trials
Phase 1
207 (75.5%)Phase 3
41 (15.0%)Phase 2
13 (4.7%)Not Applicable
6 (2.2%)Phase 4
5 (1.8%)phase_2_3
2 (0.7%)A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Crohn’s Disease
Phase 3
Completed
- Conditions
- Crohn’s Disease
News
New Study Shows TAF and Dolutegravir Superior for Second-Line HIV Treatment in Children
The CHAPAS-4 trial found that tenofovir alafenamide (TAF) plus emtricitabine (FTC) suppressed HIV in 6% more children than standard backbone treatments while being more cost-effective.
CAR T-cell Therapy Monitoring: Study Suggests Reduced REMS May Improve Accessibility
A recent study suggests that the FDA's Risk Evaluation and Mitigation Strategy (REMS) for CAR T-cell therapy may be overly restrictive, impacting patient accessibility.